EPOETIN ALFA – New warnings on severe cutaneous adverse reaction

EPOETIN ALFA – New warnings on severe cutaneous adverse reaction

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), JANSSEN PHARMACEUTICA (PTY) LTD, would like to inform you of the risk of severe cutaneous adverse reactions in patients treated with Eprex®.

2019 Apr

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance